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SURGICALTECHNIQUESSurgical treatment of residual systolic anterior motion after
otherwise successful percutaneous transluminal septal myocardial
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Lex A. van Herwerden, MD, PhD,a Utrecht, The Hague, and Rotterdam, The NetherlandsFIGURE 1. Echocardiographic images. A, Preoperative transesophageal echo
anterior mitral valve leaflet in late systole. B, Preoperative transthoracic echoca
operative epicardial echocardiographic 4-chamber view demonstrating patch of
diogram of left ventricular outflow tract indicating neither systolic anterior mo
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506 The Journal of Thoracic and Cardiovascular SurgHypertrophic obstructive cardiomyopathy (HOCM) is char-
acterized by asymmetrically distributed left ventricular hy-
pertrophy, often accompanied by left ventricular outflow
tract obstruction (LVOTO).1 LVOTO in patients with
HOCM commonly exists in addition to mitral valve abnor-
malities, such as increased mitral leaflet area, length, and
laxity, along with anterior displacement of the papillary
muscles.2 These abnormalities predispose toward systolic
anterior motion (SAM), which is a protrusion of the anterior
mitral valve leaflet into the left ventricular outflow tract,
adding to the severity of LVOTO and a variable degree of
mitral regurgitation.cardiogram of the mitral valve. Arrow shows systolic anterior motion of
rdiogram indicating an adequate trough of the ventricular septum. C, Post-
anterior mitral valve leaflet. D, Six-month postoperative M-mode echocar-
tion nor left ventricular outflow tract obstruction.
ery c August 2012
FIGURE 2. Artist’s impression of surgeon’s view of mitral valve leaflet ex-
tension (A). Surgeon’s view through oblique incision of ascending aorta on
the septal trough (B) and anteriormitral valve leaflet. The autologous pericar-
dial patch was harvested before crossclamping, measured 2.53 3.0 cm, and
was tanned with glutaraldehyde. The oval patch was inserted with a 5-0 Pro-
lene (Ethicon, Inc, Somerville, NJ) after a longitudinal split in the midline of
the anteriormitral leaflet between the trough rough zone and the aortic mitral
continuity. (Adapted with permission fromVanHerwerden LA, Ten Cate FJ.
Combined anterior mitral leaflet extension and spark erosion myectomy in
hypertrophic obstructive cardiomyopathy: echo-enhanced surgery. Oper
Tech Thorac Cardiovasc Surg Comp Atlas. 2004;9:310-8.)
Surgical TechniquesSeptal myectomy is regarded as the standard invasive
therapy to reduce septal thickness and left ventricular out-
flow tract gradient.1 Percutaneous transluminal septal myo-
cardial ablation (PTSMA) is a nonsurgical technique that
reduces septal thickness by injecting ethanol into 1 or
more septal branches of the left anterior descending coro-
nary artery.3 This results in local myocardial infarction, fol-
lowed by septal thinning, left ventricular outflow tract
widening, and left ventricular outflow tract gradient reduc-
tion. Treatment of the septal hypertrophy alone does not
change the mitral valve apparatus, however, and may lead
to residual SAM. As such, mitral valve leaflet extension
has been performed to address the abnormal motion of the
mitral valve in systole and contributes to the reduction of
LVOTO.4
The aim of this report is to stress the importance of sur-
gical extension of the anterior mitral valve leaflet in addi-
tion to myectomy as a treatment of LVOTO in patients
with HOCM. This report further illustrates that residual
LVOTO after PTSMA can be treated with an isolated mitral
valve leaflet extension.
CLINICAL SUMMARY
A 44-year-old man with HOCMwas admitted to our hos-
pital with persistent LVOTO caused by residual SAM
(Figure 1, A) after treatment with a myectomy by means
of PTSMA in 2005. Symptoms of persisting fatigue pre-
sented in 2007, and an exercise echocardiogram demon-
strated SAM. In 2010, the patient was referred to our
clinic for surgical treatment. Informed consent was ob-
tained from the patient. The septal trough caused by
PTSMA could not be improved without compromising con-
duction and septal integrity (Figure 1, B). We performed an
extension of the anterior mitral valve leaflet with an autol-
ogous glutaraldehyde-treated pericardial patch.4 The patch
was placed across the bending point of the mitral valve
where SAM was maximal to stiffen the buckling anterior
mitral valve leaflet. The patch extended the width but not
the length of the anterior mitral valve leaflet, which shifted
the centrally attached secondary chordae laterally. Finally,
because force produced by blood flow against the leaflet
is proportional to its area, the increased leaflet was pressed
posterior, with a decrease in SAM and mitral regurgitation
(Figure 2). Hemodynamically, the patchworked as a spinna-
ker sail. Figure 2 depicts the surgeon’s view. Intraoperative
transesophageal echocardiography demonstrated neither
SAM nor LVOTO (Figure 1, C). After 13 days, the patient
was discharged in sinus rhythm with a right bundle branch
block. The 6-month postoperative transthoracic echocardio-
gram also revealed neither SAM nor LVOTO (Figure 1, D).
DISCUSSION
Left ventricular septal myectomy has been the gold stan-
dard for the surgical treatment of LVOTO in patients withThe Journal of Thoracic and CaHOCM. LVOTO and mitral regurgitation may persist after
successful surgical myectomy. However, if the mitral valve
apparatus abnormalities are left untreated may cause resid-
ual SAM. Mitral valve replacement has been performed to
abolish any risk of residual SAM; however, this is associ-
ated with thromboembolic complications or bleeding events
as a result of anticoagulation therapy.5 As such, an alterna-
tive surgical procedure seems warranted to address the mi-
tral valve apparatus abnormalities present in patients with
HOCM, with the aim of reducing the risk of residual
LVOTO caused by SAM after a successful septal myec-
tomy. Moreover, LVOTO gradient is an independent predic-
tor of mortality after myecotomy.6
This case demonstrates the importance of performing
a mitral valve leaflet extension in addition to septal myec-
tomy in patients with HOCM and LVOTO. To our knowl-
edge, this case is unique because the patient had
undergone a successful myectomy by PTSMA but still
had residual LVOTO caused by SAM. This finding supports
the notion that an uncorrected enlarged anterior mitral valve
leaflet may predispose toward residual SAM after a success-
ful standard myectomy or PTSMA. Moreover, at 1-year
follow-up after mitral valve leaflet extension in additionrdiovascular Surgery c Volume 144, Number 2 507
Surgical Techniquesto septal myectomy, significant decreases in residual SAM
and superior hemodynamic results have been observed.4
In summary, we report the case of a patient with HOCM
previously treated with PTSMA but with residual LVOTO
caused by SAM. We successfully performed an isolated
mitral valve leaflet extension to address the mitral valve ap-
paratus abnormalities. This case report illustrates the impor-
tance of surgically treating the mitral valve apparatus in
addition to septal myectomy when treating patients with
HOCM for LVOTO caused by SAM.
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revascularization as a bailout for a high-risk patientDavid M. Holzhey, MD, Gerhard Schuler, MD, PhD, Friedrich W. Mohr, MD, PhD, and
Chirojit Mukherjee, MD, Leipzig, GermanyTranscatheter aortic valve implantation as a treatment op-
tion for severe aortic valve stenosis has become a routine
procedure, with encouraging results in a high-risk popula-
tion.1,2 Concomitant treatment of coronary artery disease
by percutaneous intervention has been described,3 and sin-
gle cases and small series of transcatheter mitral valve-in-
valve procedures (and even 1 double valve procedure)
have been reported.4,5 This represents the first description
of successful combination of all these procedures.CLINICAL SUMMARY
A 73-year-old man who had undergone mitral valve re-
construction and bypass surgery 12 years previously was re-
ferred to our clinic. He was in New York Heart Association
functional class IV.
Echocardiography revealed structural degeneration of
the repaired mitral valve with moderate to severe mitral
stenosis (pressure gradient maximum/mean ratio, 21/8; ef-
fective orifice area, 1.3 cm2) and grade II insufficiency.
Additionally, the aortic valve was severely stenosed, witha gradient of 56/30 mm Hg despite his poor left ventricular
function of 18%. There was moderate tricuspid insuffi-
ciency, and pulmonary arterial pressure was 66 mm Hg
greater than central venous pressure. Coronary angiogra-
phy showed patent bypass grafts; however, 2 de novo
lesions of the proximal right coronary artery needed
intervention.
The EuroSCORE was 17 points, with a logistic Euro-
SCORE of 69.4% (Society of Thoracic Surgeons risk
model not available). The heart team chose and the patient
agreed to a hybrid approach with percutaneous coronary
intervention and transapical aortic and mitral valve
implantation.
The aortic annulus was measured at 27 mm with trans-
esophageal echocardiography and computed tomography.
Selection of the mitral valve prosthesis was done by precise
computed tomographic reconstruction of the l ring, which
revealed an inner circumference of 79.5 mm, equaling an
inner diameter of 25.3 mm if pressed into a perfectly round
shape. Thus 29-mm Edwards Sapien XT valves (Edwards
Lifesciences LLC, Irvine, Calif) were selected for both
the aortic and mitral positions.Procedures
Percutaneous coronary intervention with placement of 2
drug-eluting stents in the proximal right coronary artery,
was successfully performed 4 days before the transapical
procedure (Figure 1).ery c August 2012
